Longtime fans of Minnesota’s pro teams are intensely familiar with the term “playing out the string.” It’s the accepted term for those games late in a season when your team is out of the playoff race ...

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations. For decades, the “7+3” strategy—comprising 7 days of continuous ...

Annamycin plus cytarabine achieved a 40% preliminary remission rate in relapsed AML, including patients who previously received Venclexta-based therapy. Early findings from the ongoing MIRACLE ...

Credit: Getty Images AML highlights from ASH 2025 include results from the AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies. Acute myeloid leukemia (AML) research presented at the ASH Annual ...

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies. Management of newly diagnosed acute ...

Annamycin combined with cytarabine shows promising results in relapsed/refractory AML, with median OS of 9 months, exceeding historical benchmarks. The drug's lack of cardiotoxicity allows for repeat ...

Department of Chemistry, University of Ulsan, 93 Daehak-ro, Nam-gu, Ulsan 44610, South Korea Energy Harvest-Storage Research Center (EHSRC), University of Ulsan, 93 Daehak-ro, Nam-gu, Ulsan 44610, ...

CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...

Abstract: We propose an active mode-locked optoelectronic oscillator (AML-OEO) for frequency-tunable microwave pulse generation. In the proposed AML-OEO system, an on-chip dual-drive silicon ...

Experts discussed the great advances and innovations they’ve seen this year in acute myeloid leukemia (AML) and multiple myeloma. Lin: Well, there has been a lot of excitement in both therapy and how ...